
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is showing strong financial performance, reporting a narrower net loss of $0.26 per share for Q1 2026 compared to analyst estimates of $0.32 per share. With a projected full-year net loss of $1.23 per share and a strong cash balance of $118.6 million, the company is well-positioned for future growth and has a strong runway into 2027. The positive outlook is reflected in the Buy rating and raised price target of $11 per share, indicating confidence in the company's potential for success.
Bears say
Caribou Biosciences is facing significant challenges with its clinical trials for Vispacabtagene regedleucel and CB-011, with potentially disappointing results from longer follow-up on the ANTLER trial and initial dose expansion results for CB-011. This may lead to delays in its product pipeline and impact revenue growth in the short-term, making it a risky investment for potential investors. Additionally, the company's concentration in the US market for revenue generation adds further uncertainty to its future financial performance.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares